Prasad S. Adusumilli, MD, FACS

Prasad S. Adusumilli, MD, FACS, deputy chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center, discusses the potential role of chimeric antigen receptor (CAR) T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.

Adusumilli believes CAR T cells can play a role in this space as well. We are learning a lot from the checkpoint blockade immunotherapy, the immune microenvironment and the tumors, as well as the immune resistance mechanism. The combination of these suggests to Adusumilli that in the next 5 years, CAR T-cell therapy could potentially play a role in the treatment of solid tumors.

Choosing the correct antigen and designing a CAR T cell specific to the solid tumors is important for this research. Delivery of focus of each solid tumor can be different, says Adusumilli. It is important to conduct correlative science to understand the changes in the tumor microenvironment so that next-generation CAR T cells can be developed.

<< View more resources and information regarding CAR T-cell therapy

Videos

Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.

Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors

Prasad S. Adusumilli, MD, FACS, deputy chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center, discusses where he sees chimeric antigen receptor (CAR) T-cell therapy fitting into the treatment landscape for patients with solid tumors.

Adusumilli says it is not just CAR T cells that are important but also what we are learning from checkpoint blockade immunotherapy, the immune microenvironment and the tumors, and the immune resistance mechanism. With a combination of these, Adusumilli says he is optimistic that in the next 5 years, CAR T-cell therapy will play an important role in the treatment of solid tumors.

The main message is choosing the correct antigen and designing a CAR specific to the solid tumor. Delivery of focus for each solid tumor can be different, Adusumilli says. Doing correlative studies is important for the understanding of the changes in the tumor microenvironment. This will help the development of next-generation CAR T cells.

The field is evolving rapidly, says Adusumilli. There is a greater understanding of solid tumor malignancies, and he believes combination immunotherapy will play a role in the treatment landscape moving forward.

Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.

Prasad S. Adusumilli, MD, FACS | Authors

Articles

Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors

Expert Addresses Role of CAR T-Cell Therapy in Solid Tumors